Why CVRs Are Becoming the Quiet Engine Behind Today’s Biotech Deals

The biotech sector is navigating one of the most complex market environments in recent memory. Volatile valuations, cautious capital, shifting regulatory expectations, and unpredictable clinical timelines have made it harder than ever for buyers and sellers to agree on what a biotech asset is truly worth. Deals that would have closed easily a decade ago now stall because neither party wants to misprice uncertainty.

Into this landscape, a once-niche financial instrument has re-emerged as a powerful mechanism for getting transactions done: the Contingent Value Right, or CVR.

CVRs are not new, but the surge in their use tells a larger story about how the industry is reshaping risk, value, and deal structure.

What a CVR Actually Does

A Contingent Value Right is a simple idea: the buyer pays part of the acquisition price upfront, and the remainder only if future milestones are met.

Those milestones usually fall into one of three buckets:

1. Regulatory: approval by a health authority.
2. Clinical: success of a trial or a key study readout.
3. Commercial: achieving certain sales thresholds.

If the milestone happens, the seller gets paid.
If it doesn’t, the buyer pays nothing beyond the initial amount.

In essence, a CVR is a structured way to acknowledge uncertainty rather than ignore it.

Why CVRs Are Surging Now

The renewed popularity of CVRs is tied directly to the conditions shaping today’s biotech market.

1. Valuation gaps are widening

Sellers believe in their pipelines. Buyers believe in pricing risk. Those perspectives rarely align in the current climate. CVRs bridge the gap without forcing either side into a valuation they don’t trust.

2. Cash conservation matters

Acquirers are managing budgets more carefully, and CVRs help reduce upfront spend while still offering competitive deal terms.

3. More assets are in ambiguous territory

The industry is full of programs that are scientifically promising but not yet “derisked.” CVRs allow buyers to proceed without taking full binary risk and allow sellers to preserve upside.

4. They help avoid deal failure

Many deals that might otherwise collapse at the negotiation table can move forward because CVRs make it possible to defer judgment until the science speaks.

The Upside and the Risk

CVRs can unlock tremendous value for both sides.

For sellers, they provide a path to acquisitions even when market conditions are unfavorable. They also allow founders, early investors, and employees to capture upside if their long-term conviction turns out to be right.

For buyers, CVRs are a disciplined way to price uncertainty, preserving capital while still keeping the door open to high-value outcomes.

However, the risks are real:

• Milestones may never be reached, resulting in no additional payout.
• Timelines can stretch for years with no liquidity.
• There can be disputes about performance, progress, or the buyer’s effort toward achieving milestones.
• Complex CVR terms can create misunderstandings between stakeholders.

CVRs are useful precisely because they acknowledge uncertainty. But they do not eliminate it.

What This Signals for the Future of Biotech Deal-Making

The rise of CVRs reflects a deeper structural shift:

• Deal-making is moving toward outcome-based value rather than projected value.
• Incentives between buyer and seller are becoming more aligned.
• Risk-sharing is becoming the defining characteristic of the modern biotech transaction.
• Companies with earlier-stage or ambiguous assets still have viable exit paths.

In many ways, CVRs are a mirror held up to the state of the industry. They reveal a market that is innovative, resourceful, and increasingly realistic about the unknowns that shape biotech success.

What Executives, Investors, and Founders Should Take Away

If you are evaluating an acquisition, partnership, or exit strategy, understanding CVRs is now essential.

• For founders and boards: CVRs can rescue deals that might otherwise fail and preserve long-term upside.
• For investors: the structure demands careful due diligence on what milestones truly represent viable value.
• For acquirers: CVRs help allocate capital more efficiently without compromising strategic ambition.

Above all, CVRs demonstrate that in uncertain markets, the most effective deal structures are those that make uncertainty explicit and measurable.

Conclusion

CVRs are becoming a standard feature of biotech transactions not because they are trendy, but because they solve a fundamental problem: how to assign value when the future is not yet knowable. They are a pragmatic response to market volatility and scientific uncertainty—and a sign that the industry is evolving toward more disciplined, evidence-driven deal-making.

Their rise underscores a broader reality: in biotech, value is increasingly tied not just to potential, but to proof. And CVRs are one of the clearest reflections of that shift.